Injectable extended-release naltrexone (XR-NTX) for opioid dependence: Long-term safety and effectiveness

Addiction

Volumn 108, Issue 9, 2013, Pages 1628-1637

  Krupitsky, Evgeny ^a   Nunes, Edward V ^b   Ling, Walter ^c   Gastfriend, David R ^d   Memisoglu, Asli ^d   Silverman, Bernard L ^d  

^a Bekhterev St Petersburg Psychoneurological Research Institute   (Russian Federation)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ALKERMES INC   (United States)

Author keywords

Craving; Depot naltrexone; Extended release naltrexone; Heroin dependence; Injectable naltrexone; Long term safety; Naltrexone; Opioid dependence; Sustained release formulations

Indexed keywords

DELAYED RELEASE FORMULATION; NALTREXONE; NARCOTIC ANTAGONIST;

ADULT; CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; OPIOID-RELATED DISORDERS; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; SELF REPORT; ARTICLE; CONTROLLED CLINICAL TRIAL; DEPOT NALTREXONE; EXTENDED-RELEASE NALTREXONE; HEROIN DEPENDENCE; INJECTABLE NALTREXONE; LONG-TERM SAFETY; OPIATE ADDICTION; RECURRENT DISEASE; SUSTAINED RELEASE FORMULATIONS; WITHDRAWAL SYNDROME;

ADULT; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MEDICATION ADHERENCE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; SECONDARY PREVENTION; SELF REPORT; RECURRENCE;

CRAVING; DEPOT NALTREXONE; EXTENDED-RELEASE NALTREXONE; HEROIN DEPENDENCE; INJECTABLE NALTREXONE; LONG-TERM SAFETY; NALTREXONE; OPIOID DEPENDENCE; SUSTAINED RELEASE FORMULATIONS;

EID: 84882272987     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12208     Document Type: Article

References (26)

1. Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4586 Findings). Rockville, MD: Substance Abuse & Mental Health Services Administration-the US Department of Health and Human Services; 2010.
2. UNODC. World Drug Report 2010 (United Nations Publication, Sales No. E.10.XI.13). 2010. Available at: http://www.unodc.org/documents/wdr/WDR_2010/World_Drug_Report_2010_lo-res.pdf (accessed 22 August 2012). (Archived by WebCite® at http://www.webcitation.org/60NzBlRJC).
3. Hser Y., Anglin M. D., Powers K. A 24-year follow-up of California narcotics addicts. Arch Gen Psychiatry 1993; 50: 577-584.
4. Wilcox H. C., Conner K. R., Caine E. D. Association of alcohol and drug use disorders and completed suicide: an empirical review of cohort studies. Drug Alcohol Depend 2004; 76S: S11-S19.
5. National Institute of Drug Abuse. NIDA Research Report-Heroin Abuse and Addiction. NIH Publication No. 05-4165, 2005.
6. Leshner A. I. Drug addiction research: moving toward the 21st century. Drug Alcohol Depend 1998; 51: 5-7.
7. McLellan A. T., McKay J. R. Components of successful addiction treatment. In: Graham A. W., Schultz T. K., Mayo-Smith M. F., Ries R. K., Wilford B. B., editors. Principles of Addiction Medicine, 3rd edn. Chevy Chase: American Society of Addiction Medicine; 2003, p. 429-442.
8. Mattick R. P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008; 2: CD002207.
9. Minozzi S., Amato L., Vecchi S., Davoli M., Kirchmayer U., Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2011; 4: CD001333.
10. Mattick R. P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; 3: CD002209.
11. Krupitsky E. M., Zvartau E. E., Masalov D. V., Tsoi M. V., Burakov A. M., Egorova V. Y. etal. Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat 2004; 26: 285-294.
12. Fudala P. J., Bridge T. P., Herbert S., Williford W. O., Chiang C. N., Jones K. etal. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003; 349: 949-958.
13. Newman R., Whitehill W. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet 1979; 8: 485-488.
14. Dekimpe M. G., Van De Gucht L. M. V., Hanssens D. M., Powers K. I. Long run abstinence after narcotics abuse: what are the odds? Manage Sci 1998; 44: 1478-1492.
15. Sullivan M., Garawi F., Bisaga A., Comer S. D., Carpenter K., Raby W. N. etal. Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend 2007; 91: 289-292.
16. Krupitsky E., Nunes E. V., Ling W., Illeperuma A., Gastfriend D. R., Silverman B. L. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011; 377: 1506-1513.
17. Garbutt J. C., Kranzler H. R., O'Malley S. S., Gastfriend D. R., Pettinati H. M., Silverman B. L. etal. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005; 293: 1617-1625.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
19. Mercer D., Woody G. E. Individual Drug Counseling. NIH Publication Number 99-4380; Rockville, MD: National Institute on Drug Abuse; 1999.
20. Sobell L. C., Sobell M. B. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten R. Z., Allen J. P., editors. Measuring Alcohol Consumption: Psychosocial and Biological Methods, Totowa, NJ: The Humana Press; 1992, p. 41-72.
21. McLellan A. T., Kushner H., Metzger D., Peters R., Smith I. etal. The fifth edition of the addiction severity index. J Subst Abuse Treat 1992; 9: 199-213.
22. Ware J. E., Kosinski M., Dewey J. E. How to Score Version Two of the SF-36 Health Survey. Lincoln RI: QualityMetric Incorporated; 2000.
23. Euroqol Group. Euroqol-A new facility for the measurement of health-related quality of life. Health Policy (New York) 1990; 16: 199-208.
24. Guy W. ECDEU Assessment for Psychopharmacology, Revised Edition. Rockville, MD: NIMH Publication; 1976, p. 76-338.
25. Lucey M. R., Silverman B. L., Illeperuma A., O'Brien C. P. Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics. Alcohol Clin Exp Res 2008; 32: 498-504.
26. Baser O., Chalk M., Fiellin D. A., Gastfriend D. R. Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care 2011; 17: S235-248.